natgillin/translations-raw huggingface dataset:
Replagal was originally authorised under ‘exceptional circumstances’, because as the disease is rare, limited information was available at the time of approval.
Replagal a fost inițial autorizat în „condiții excepționale”, deoarece, din cauză că boala este rară, informațiile puse la dispoziție la momentul aprobării erau limitate.
Replication of the parasite damages the dog’s intestinal mucosa, which may cause enteritis.
Multiplicarea paraziţilor deteriorează mucoasa intestinală a câinilor, poate determina enterită.
Replicon variants generated from patient-derived sequences showed similar results.
Tulpinile replicon generate de secvenţele derivate de la pacienţi au demonstrat rezultate similare.
Report any changes to your doctor.
Raportaţi orice modificare medicului dumneavoastră.
Report any pregnancy, neuropathy or other adverse events to Celgene and the local health authority (if applicable to a Member State) using the forms provided in the “Educational Healthcare Professional’s Kit”
Raportarea oricărei sarcini, neuropatii sau altor reacţii adverse la Celgene şi autorităţii competente locale (dacă este cazul unui stat membru) folosind formularele furnizate în „Setul de informare pentru personalul medical”
report by 31
final al
report of the
pentru studiul
Report submission is no later than day 22 (i.e. the following Monday).
Depunerea raportului nu se va face mai târziu de ziua 22 (adică în ziua de luni care urmează).
reported 11
Simptomatologie
Reported adverse reactions are listed below, by system organ class and by frequency.
Reacţiile adverse raportate sunt prezentate mai jos, în funcţie de clasificarea pe aparate, sisteme şi organe şi de frecvenţă.
Reported adverse reactions listed in Table 5 are based on experience from the two multicentre children and adolescents clinical trials using ribavirin with interferon alfa-2b or peginterferon alfa-2b.
Reacţiile adverse enumerate în Tabelul 5 se bazează pe experienţa din două studii clinice multicentrice la copii şi adolescenţi utilizând ribavirină în asociere cu interferon alfa-2b sau peginterferon alfa-2b.
reported by the parents as adversely affecting the child’s daily activities For both vaccination groups, the majority of the reactions were short lasting.
În ambele grupuri vaccinate, majoritatea reacţiilor adverse au fost de scurtă durată.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with impaired renal failure or acute worsening of renal function.
Cazurile de acidoză lactică raportate la pacienţi trataţi cu metformină au apărut în principal la pacienţi diabetici cu insuficienţă renală sau agravare acută a disfuncţiei renale.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Cazurile de acidoză lactică raportate la pacienţii trataţi cu metformin au apărut în principal la pacienţii diabetici cu insuficienţă renală semnificativă.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Cazurile de acidoză lactică raportate la pacienţii trataţi cu metformin au apărut, în principal, la pacienţii diabetici cu insuficienţă renală semnificativă.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Cazurile de acidoză lactică raportate la pacienţii trataţi cu metformină au apărut în principal la pacienţii diabetici cu insuficienţă renală semnificativă.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Cazurile raportate de acidoză lactică la pacienţii pe metformin au avut loc mai ales la pacienţi cu insuficienţă renală semnificativă.
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure.
Cazurile raportate de acidoză lactică la pacienţii trataţi cu metformină s-au produs în principal la pacienţii diabetici cu insuficienţă renală semnificativă.
Reported commonly in placebo
Reacţii adverse raportate frecvent cu placebo
Reported experience with overdose is limited.
Experienţa cu cazurile de supradozaj raportată este limitată.
Reported over 3 years in a COPD study
Raportate pe o perioadă de 3 ani într-un studiu cu BPOC
Reported rates of recurrent rash following a switch from nevirapine to efavirenz therapy, primarily based on retrospective cohort data from published literature, range from 13 to 18%, comparable to the rate observed in patients treated with efavirenz in clinical studies (see section 4.4).
Ratele de recurenţă a erupţiilor cutanate tranzitorii raportate ca urmare a trecerii de la tratamentul cu nevirapină la cel cu efavirenz, bazate în principal pe datele de cohortă retrospective provenite din literatura de specialitate, interval de la 13 până la 18 %, comparabil cu rata observată la pacienţii trataţi cu efavirenz în studiile clinice (vezi pct.
Reported serious infections, some with fatal outcome, included active tuberculosis, which may present with intrapulmonary or extrapulmonary disease, invasive pulmonary infections, including candidiasis, aspergillosis, coccidioidomycosis and pneumocystis jirovecii, pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis.
Infecţiile grave raportate, unele cu evoluţie letală, includ tuberculoza activă, care poate apărea cu boala intrapulmonară sau extrapulmonară, infecţii pulmonare invazive, inclusiv candidoză, aspergiloză, coccidiodomicoză şi infecţie cu Pneumocystis jiroveci, pneumonie, celulită, herpes zoster, gastroenterită, diverticulită, septicemie şi artrită bacteriană.
Reported side effects following the use of OPTISON:
Reacţiile adverse raportate ca urmare a utilizării OPTISON:
Reported symptoms of overdose include neutropenia, anaemia, thrombocytopenia, mucositis, sensory polyneuropathy and rash.
Simptomele de supradozaj raportate includ neutropenie, anemie, trombocitopenie, mucozită, polineuropatie senzorială şi erupţie cutanată.
Reported very commonly in placebo
Reacţii adverse raportate foarte frecvent cu placebo
reported with a higher incidence (very common) in patients who received two concurrent injections of Xiapex in the same hand compared with subjects treated with up to three single injections in the Phase 3 placebo-controlled pivotal studies in Dupuytren’s contracture.
raportată cu o incidență crescută (foarte frecvent) la pacienții cărora li s-au administrat două injecții concomitente cu Xiapex la nivelul aceleiași mâini, comparativ cu subiecții tratați cu până la trei injecții unice în studiile pivot de fază 3 controlate cu placebo, efectuate pentru contractura Dupuytren.
reported with fatal
câteva cazuri cu
reported with fatal
evoluţie letală,
Reporting of medication errors or any side effects
Raportarea erorilor de medicație sau oricăror efecte secundare
Reporting of medication errors or any side effects.
Raportarea erorilor de medicaţie sau a oricăror reacţii adverse.
Reporting of medication errors or any side effects.
Raportarea erorilor de medicație sau orice reacţii adverse.
Reporting of serious adverse drug reactions
Raportarea reacţiilor adverse grave
Reporting of serious adverse events(reminder aid)
Raportarea reacţiilor adverse grave (îndrumar de notificare)
Reporting of serious adverse reactions
Raportarea reacţiilor adverse grave
Reporting of side effe cts
Raportarea reacţiilor adverse
Reporting of side effect
Raportarea reacţiilor adverse
Reporting of side effects
Raportarea reacţiilor adverse suspectate
Reporting of side effects
Raportarea reacţiilor adverse:
Reporting of side effects
Raportarea reacților adverse
Reporting of side effects
Reacţii adverse raportate
Reporting of side effects
Reportarea reacţiilor adverse
Reporting of side effects → If you get any side effects, talk to your doctor or pharmacist.
Raportarea reacţiilor adverse → Dacă manifestaţi orice reacţii adverse, adresaţi-vă medicului dumneavoastră sau farmacistului.
Reporting of side effects.
Raportarea reacţiilor adverse
Reporting of suspected adverse reactions
4.4 Raportarea reacţiilor adverse suspectate
Reporting of suspected adverse reactions
4.4. Raportarea reacţiilor adverse suspectate
Reporting suspected adverse reactions after authorisation of the medical product is important.
Raportarea reacţiilor adverse suspectate după autorizarea medicamentului este importantă.
Reporting suspected adverse reactions after authorisation of the medicial product is important.
Raportarea reacţiilor adverse suspectate după autorizarea medicamentului este importantă.
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Dacă manifestaţi orice reacţii adverse, adresaţi-vă medicului dumneavoastră sau farmacistului.
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Este importantă raportarea reacţiilor adverse suspectate după autorizarea medicamentului..
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Este importantă raportarea reacțiilor adverse suspectate după autorizarea medicamentului .
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Este importantă raportarea recțiilor adverse suspectate după autorizarea medicamentului.
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Raportarea reacţiilor adverse suspectate după autorizarea medicamentului este importantă.
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Raportarea reacţiilor adverse suspectate după autorizarea de punere pe piaţă a medicamentului este importantă.
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Raportarea reacţiilor adverse suspectate după punerea pe piaţă a medicamentului este importantă.
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Raportarea reacţiilor adverse suspectate dupăautorizarea medicamentului este importantă.
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Raportarea reacțiilor adverse suspectate după monitorizarea medicamentului este importantă.
Reporting suspected adverse reactions afterauthorisation of themedicinal product is important.
Raportarea reacţiilor adverse suspectate după autorizarea medicamentului este importantă.
Reporting to be fortnightly for the first 3 months of the pandemic.
Raportarea se va face la fiecare 2 săptămâni, în primele 3 luni de pandemie.
Reporting to be monthly for the first 6 months.
Raportarea se va face lunar în primele 6 luni.
Reporting to be monthly for the first 6 months.
Raportarea trebuie să fie lunară în primele 6 luni.
Reportng suspected adverse reactions after authorisation of the medicinal product is important.
Raportarea reacţiilor adverse suspectate după autorizarea medicamentului este importantă.
Reports - with each
de studiu - la
Reports from published literature confirmed that methylthioninium chloride is effective in treating methaemoglobinaemia that has been caused by exposure to a medicine or chemical in adults and children.
Rapoartele din literatura de specialitate publicată au confirmat eficacitatea clorurii de metiltioniniu în tratamentul methemoglobinemiei cauzate de expunerea la un medicament sau produs chimic la adulți și copii.
Reports from the sub-
Rapoartele din
Reports have been received from post-approval marketing experience in association with the use of Enurev Breezhaler.
Au fost primite raportări din experienţa de după punerea pe piaţă cu privire la administrarea Enurev Breezhaler.
Reports have been received from post-approval marketing experience in association with the use of Seebri Breezhaler.
Au fost primite raportări din experienţa de după punerea pe piaţă cu privire la administrarea Seebri Breezhaler.
Reports have been received from post-approval marketing experience in association with the use of Tovanor Breezhaler.
Au fost primite raportări din experienţa de după punerea pe piaţă cu privire la administrarea Tovanor Breezhaler.
Reports have included death and life threatening acute respiratory failure with rapid onset (see section 4.8).
Raportările au inclus deces şi insuficienţă respiratorie acută cu debut rapid, care pune viaţa în pericol (vezi pct.
Reports in the literature indicate that treatment of another indication with dopaminergic medicinal products can result in augmentation.
Datele din literatură indică faptul că tratamentul unei alte afecţiuni cu medicamente dopaminergice poate conduce la exacerbarea acesteia.
Reports in the literature indicate that treatment of another indication with dopaminergic medicinal products can result in augmentation.
Datele din literatură indică faptul că, în cazul altei indicaţii, tratamentul cu medicamente dopaminergice poate conduce la exacerbarea acesteia.
reports of abnormal liver tests values,
valori anormale ale testelor de laborator ale ficatului,
Reports of acute toxicity and/or deaths following hydrocortisone overdose are rare.
Raportările de toxicitate acută şi/sau decese în urma supradozajului cu hidrocortizon sunt rare.
Reports of extravasation with subsequent infusion site reactions including e.g. infusion site dermatitis, infusion site desquamation, and infusion site ulcer have been received.
S-au primit raportări privind extravazarea cu reacţii ulterioare la nivelul locului de perfuzie, de exemplu, dermatită la locul perfuziei, descuamare la locul perfuziei şi ulcere la locul perfuziei.
Reports of fistulae that involve areas of the body other than stomach or intestines were observed across various indications.
Au fost raportate cazuri observate de fistule care au implicat alte regiuni ale corpului în afară de stomac sau de intestine, în diverse indicaţii.
Reports of gastrointestinal perforation on tocilizumab were primarily reported as complications of diverticulitis including generalised purulent peritonitis, lower gastrointestinal perforation, fistulae and abscess.
Rapoartele de perforaţii gastro-intestinale asociate cu tocilizumab, au fost descrise iniţial ca şi complicaţii ale diverticulitei, incluzând peritonita purulentă generalizată, perforaţii gastro-intestinale inferioare, fistule şi abcese.
Reports of overdoses with oseltamivir have been received from clinical trials and during post- marketing experience.
Au fost primite raportări de supradozaj cu oseltamivir din studiile clinice şi ulterior punerii pe piaţă.
Reports of serious infection have been received in post-marketing surveillance including device- related infection, device-related sepsis, pneumonia, sepsis, bacteraemia, and urinary tract infection.
În timpul supravegherii ulterioare punerii pe piaţă s-au primit raportări privind infecţii grave, inclusiv infecţie asociată dispozitivului, sepsis asociat dispozitivului, pneumonie, sepsis, bacteremie şi infecţii ale tractului urinar.
Reports of severe abdominal pain and diarrhoea have been observed in clinical trials with the 25 mg dose, typically occurring shortly after initiation of treatment.
În studiile clinice cu doza de 25 mg au fost raportate diaree şi durere abdominală severă, care apar în general la scurt timp după iniţierea tratamentului.
Reports of significant sequelae associated with thrombocytopenia including fatalities due to tumour bleeds have been infrequent.
Au fost raportate mai puţin frecvent complicaţii semnificative ale trombocitopeniei, inclusiv decese datorate sângerărilor tumorale..
Reports of significant sequelae associated with thrombocytopenia including fatalities due to tumour bleeds have been infrequent.
Au fost raportate mai puţin frecvent complicaţii semnificative ale trombocitopeniei, incluzând decese datorate sângerărilor tumorale.
Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been received in the postmarketing period (see section 4.8).
În perioada ulterioară punerii pe piaţă au fost raportate diverse malignităţi (incluzând carcinoame ale sânului şi pulmonare, precum şi limfoame) (vezi pct.
Reports on recruitment progress of the patient surveillance database will be analysed and reported to the CHMP at the time of PSURs (for safety) and of the Annual Re- assessments (for efficacy and safety).
Rapoartele privind progresele de recrutare din baza de date de supraveghere a pacienţilor vor fi analizate şi transmise către CHMP în momentul RPAS-urilor (pentru siguranţă) şi al reevaluărilor anuale (pentru eficacitate şi siguranţă).
Representative Office in Latvia
Representative Office in Latvia Meza Str.
Reproducti ve system and breast disorders
Tulburări ale aparatulu i genital şi sânului
Reproduction is authorised provided the source is acknowledged.
Mycoplasma hyopneumoniae.
Reproduction is authorised provided the source is acknowledged.
Pentru mai multe informaţii, consultaţi prospectul.
Reproduction is authorised provided the source is acknowledged.
Pentru mai multe informații, consultați prospectul.
Reproduction is authorised provided the source is acknowledged.
Reproducerea este autorizată cu condiția menționării sursei.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. acestora.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. acizilor nucleici ADN şi ARN virali, care sunt necesari pentru ca viruşii să supravieţuiască şi să se înmulţească.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. acţiune mai lungă.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. administrat mai rar pacienților care au probleme cu rinichii.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. administrează cu ajutorul unui inhalator diferit.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. autolog).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. autorizat în Uniunea Europeană (UE), denumit Abilify.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. boala stagnează și reacțiile adverse sunt tolerabile.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. care menține mediul vaginal umed.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. care măresc riscul de apariție a reacțiilor adverse.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. clinică a pacientului.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. comprimatului.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. continuat cât timp pacientul prezintă beneficii terapeutice.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. cu ajutorul seringii furnizate pentru administrarea pe cale orală.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. cunoscută sub denumirea de „tehnologia ADN-ului recombinant”.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. de calciu determină contracţia muşchiului cardiac.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. de medicamente care pot afecta modul în care este metabolizat Toviaz în organism.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. de tratament de 28 de zile.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. descompus, decât atunci când ajung în intestin.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. descompusă până când ajunge în intestin.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. dozei.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. efectele secundare devin prea severe.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. extinderea infecției în corp este încetinită.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. ficatului) sau dacă ficatul pacientului nu funcționează corespunzător.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. fiecare şase luni.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. fiind „străine” şi produce anticorpi pentru a se apăra împotriva acestora.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. fiind „străin” și produce anticorpi împotriva acestuia.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. forma unei injecţii intramusculare profunde.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. formă de comprimate de 20 mg.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. fosfat din sânge.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. funcție de medicamentele împreună cu care se administrează și de starea pacientului.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. greu de tratat.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hormonului, ceea ce duce la dilatarea vaselor de sânge.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hormonului, permiţând dilatarea vaselor de sânge.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. impună întreruperea definitivă a tratamentului.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. injecta singuri după ce au fost instruiţi în mod corespunzător.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. instructaj efectuat de un medic sau o asistentă.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. interpretarea scanărilor cu Vizamyl.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. medicamente poate fi necesară reducerea dozelor.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. medicamentul, după ce au fost instruiți în mod adecvat.